Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab plus antihistamines vs antihistamines alone for acute urticaria
ChiCTR2500107137Phase 4Not yet recruiting
- Sponsor
- The First Hospital of Hebei Medical University
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of omalizumab in acute urticaria (2 arms), sponsored by The First Hospital of Hebei Medical University. Primary endpoint: Change in daily UAS score from baseline to day 7. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
omalizumab
03
Conditions
acute urticaria
Beyond the preview
Go deeper on ChiCTR2500107137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107137.